[1]CurrentPatentAssignee:MERCK&COINC-WO2005/110414,2005,A2Locationinpatent:Page/Pagecolumn101
[1]Patent:WO2005/110414,2005,A2
Title: Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes.
Journal: Antiviral research 20111101
Title: Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.
Journal: Biochemistry 20100928
Title: Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Journal: Journal of virology 20100901
Title: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Journal: Virology 20100705
Title: L. Van Wesenbeeck, E. Rondelez, M. Feyaerts, et al. Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates .Antimicrob. Agents Chemother. 2011, 55 (1): 321-325
Title: Muhammad Esa Seegulam, Lee Ratner. Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1. Antimicrob. Agents Chemother. 2011, 55 (5): 2011-2017
Title: Tamara Bar-Magen1, Richard D. Sloan1, Daniel A. Donahue1, et al. Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor. J. Virol. 2010, 84(18): 9210-9216
Title: Laith Q Al-Mawsawi, Rasha I Al-Safi, Nouri Neamati. Anti-infectives Clinical progress of HIV-1 integrase inhibitors. 2008, 13(2): Pages 213-225
Title: Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25.
